Prognostic value of Day 14 measurable residual disease in acute myeloid leukemia treated with venetoclax and azacitidine
Results in the MRD<sup>14-neg</sup> group were better than in the MRD<sup>14-pos</sup> group, and the prognosis for patients with AML was better when there was CSF3R<sup>neg</sup> and transplantation. Additionally, for patients with AML with MRD<sup>14-pos</sup>, consolidation with transplantation may increase survival.
Authors
- Junjie Cao (ORCID: https://orcid.org/0000-0003-0997-4293)
- Jiaying Lian
- Peipei Ye
- Dong Chen (ORCID: https://orcid.org/0000-0002-8904-9307)
- Ying Chen (ORCID: https://orcid.org/0009-0005-8351-6620)
- Ying Lu (ORCID: https://orcid.org/0000-0003-2960-3131)
- Xiaowei Shi
- Xuhui Liu (ORCID: https://orcid.org/0000-0002-6460-6787)
- Qingqing Lin (ORCID: https://orcid.org/0000-0001-6415-5579)
- Shuangyue Li (ORCID: https://orcid.org/0000-0003-2897-4205)
- Jiaojiao Yuan
- Renzhi Pei
- Xianxu Zhuang
Institutions
- Ningbo University (CN)
Publication Details
- Journal
- Cancer
- Published
- 2025-08-26
- DOI
- https://doi.org/10.1002/cncr.70053
- Citations
- 1
- Primary Topic
- Acute Myeloid Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 1.77